Sugi Predict

Sugi Predict / Compounds / SCHEMBL348234

SCHEMBL348234

SCHEMBL348234

CC(C)(C)NC(=O)c1ccc(CN2CCN(C(=O)c3ccc(NC(=O)NC4CCC4)c(F)c3)CC2)o1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ EPHX2 P34913 3/20 0.40
▸ PRKAA2 P54646 6/20 0.40
▸ PRKAB2 O43741 3/20 0.40
▸ PRKAG1 P54619 3/20 0.40
▸ PRKAA1 Q13131 3/20 0.40
▸ PRKAG3 Q9UGI9 3/20 0.40
▸ PRKAG2 Q9UGJ0 3/20 0.40
▸ PRKAB1 Q9Y478 3/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.39
▸ ACKR3 P25106 2/20 0.38
▸ SRPK1 Q96SB4 1/20 0.38
▸ FASN P49327 1/20 0.37
▸ HRH3 Q9Y5N1 1/20 0.37
▸ KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL347102 0.92 NPC1 (0.44) L3MBTL1EPHX2PRKAA2PRKAB2PRKAG1
SCHEMBL348091 0.91 PDK1 (0.42) PRKAA2PRKAB2PRKAG1PRKAA1PRKAG3
SCHEMBL347867 0.88 TP53 (0.43) EPHX2ACKR3SRPK1FASNKMT2A
SCHEMBL348005 0.87 EPHX2 (0.40) L3MBTL1EPHX2PRKAA2PRKAB2PRKAG1
SCHEMBL347576 0.86 EPHX2 (0.40) EPHX2ALDH1A1ACKR3SRPK1HRH3
SCHEMBL15310312 0.85 EPHX2 (0.44) L3MBTL1EPHX2PRKAA2PRKAB2PRKAG1
SCHEMBL1018507 0.85 ACKR3 (0.46) L3MBTL1PRKAA2PRKAB2PRKAG1PRKAA1
SCHEMBL347836 0.85 HRH3 (0.39) EPHX2POLBALDH1A1SRPK1FASN
SCHEMBL348833 0.85 HRH3 (0.40) L3MBTL1EPHX2PRKAA2PRKAB2PRKAG1
SCHEMBL15310292 0.84 MAPK1 (0.41) EPHX2ALDH1A1ACKR3SRPK1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8759352-B2 1-(4-ureidobenzoyl)piperazine derivatives MERCK SHARP & DOHME B.V. (NL) 2014-06-24 — — US claimed
EP-2318368-B1 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES MERCK SHARP & DOHME (NL) 2013-10-16 — — EP claimed
US-20120015958-A1 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES N.V. ORGANON (NL) 2012-01-19 — — US claimed
US-20230338314-A1 METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS THE ROCKEFELLER UNIVERSITY (US) 2023-10-26 — — US disclosed
US-11648220-B2 Methods for the treatment of myeloid derived suppressor cells related disorders THE ROCKEFELLER UNIVERSITY (US) 2023-05-16 — — US disclosed
US-20190125745-A1 TREATMENT AND DIAGNOSIS OF CANCER RGENIX, INC. 2019-05-02 — — US disclosed
US-20190029984-A1 METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS THE ROCKEFELLER UNIVERSITY (US) 2019-01-31 — — US disclosed
WO-2018222975-A1 METHODS FOR THE TREATMENT OF CANCER RGENIX, INC. (US) 2018-12-06 — — WO disclosed
EP-3402477-A2 METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS The Rockefeller University (US) 2018-11-21 — — EP disclosed
WO-2017123568-A2 METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS THE ROCKEFELLER UNIVERSITY (US) 2017-07-20 — — WO disclosed
WO-2016100619-A2 TREATMENT AND DIAGNOSIS OF CANCER RGENIX, INC. (US) 2016-06-23 — — WO disclosed
US-8759352-B2 1-(4-ureidobenzoyl)piperazine derivatives MERCK SHARP & DOHME B.V. (NL) 2014-06-24 — — US disclosed
US-8759352-B2 1-(4-ureidobenzoyl)piperazine derivatives MERCK SHARP & DOHME B.V. (NL) 2014-06-24 — — US disclosed
EP-2318368-B1 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES MERCK SHARP & DOHME (NL) 2013-10-16 — — EP disclosed
US-20120015958-A1 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES N.V. ORGANON (NL) 2012-01-19 — — US disclosed
US-20120015958-A1 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES N.V. ORGANON (NL) 2012-01-19 — — US disclosed
US-20110286969-A1 DEUTERATED COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS SCHERING CORPORATION (US) 2011-11-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11648220-B2 Methods for the treatment of myeloid derived suppressor cells related disorders NR1H3, NR1H2, MCL1 L3MBTL1 1467/4885EPHX2 1489/4885PRKAA2 1404/4885
US-20230338314-A1 METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS NR1H3, NR1H2, MCL1 L3MBTL1 1467/4885EPHX2 1489/4885PRKAA2 1404/4885
US-20190029984-A1 METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS NR1H3, NR1H2, MCL1 L3MBTL1 1467/4885EPHX2 1489/4885PRKAA2 1404/4885
US-20190125745-A1 TREATMENT AND DIAGNOSIS OF CANCER NR1H4, NR1H3, NR1H2 L3MBTL1 4811/4885EPHX2 948/4885PRKAA2 2620/4885
US-20120015958-A1 1-(4-UREIDOBENZOYL)PIPERAZINE DERIVATIVES NPC1, ABCB11, NPC1L1 L3MBTL1 3842/4885EPHX2 1501/4885PRKAA2 4031/4885
US-20110286969-A1 DEUTERATED COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS PEPD, PREP, ACE L3MBTL1 3990/4885EPHX2 1554/4885PRKAA2 3355/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.